NCT04225533View on ClinicalTrials.gov

SP16 Inflammatory Response Inhibition Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 24, 2020

Primary Completion Date

January 4, 2021

Study Completion Date

December 21, 2021

Conditions
Myocardial InfarctionInflammation
Interventions
DRUG

SP16

All patients will receive a single dose of SP16

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
collaborator

Virginia Commonwealth University

OTHER

lead

Serpin Pharma, LLC

OTHER

NCT04225533 - SP16 Inflammatory Response Inhibition Trial | Biotech Hunter | Biotech Hunter